Immunoprecise Antibodies Ltd (IPA) — Cash Flow Reinvestment Rate

Latest as of October 2020: 3.25x

Immunoprecise Antibodies Ltd (IPA) has a Cash Flow Reinvestment Rate of 3.25x as of October 2020, reinvesting $1.43 Million (capex $715.21K plus investments $-715.21K) from operating cash flow of $440.23K. Check IPA operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

Reinvestment Rate

3.25x
(Capex + Investments) / Operating CF

Total Reinvested

$1.43 Million
Capex + Investments

Operating Cash Flow

$440.23K
USD

Capital Expenditures

$715.21K
USD

Immunoprecise Antibodies Ltd Cash Flow Reinvestment Rate (2016–2016)

Historical reinvestment intensity for Immunoprecise Antibodies Ltd across 1 annual periods. Explore Immunoprecise Antibodies Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Immunoprecise Antibodies Ltd (2016–2016)

Year-by-year capital reinvestment analysis for Immunoprecise Antibodies Ltd. For live market cap and broader valuation context, see how much is Immunoprecise Antibodies Ltd worth.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2016 0.06x $17.48K $284.09K $17.48K
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow